Popularity #717Earnings are out
ABVX · NASDAQ · Biotechnology

Abivax (ADR) (ABVX)

Develops oral obefazimod for ulcerative colitis and Crohn's disease.

$98.51
After hours+0.24 (+0.24%)
At close$98.27(−5.01%)
  1. Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

    Zacks Investment ResearchPrice target